Several BTK inhibitors including evobrutinib,297 spebrutinib,294 branebrutinib, 298 and HM71224299 have been assessed in clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythaematosus, and remitting multiple sclerosis. The gene discussed is BTK; the disease is autoimmune disease.